Bioventus (BVS) to Release Quarterly Earnings on Tuesday

Bioventus (NYSE:BVS) will be announcing its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Bioventus has set its FY 2024 guidance at 0.120-0.200 EPS.Investors interested in registering for the company’s conference call can do so using this link.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. Bioventus had a positive return on equity of 2.25% and a negative net margin of 30.49%. The business had revenue of $135.42 million during the quarter, compared to analysts’ expectations of $124.84 million. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioventus Stock Performance

NYSE BVS opened at $3.97 on Monday. Bioventus has a 1-year low of $0.86 and a 1-year high of $6.08. The company has a market capitalization of $314.29 million, a P/E ratio of -1.58 and a beta of 0.63. The business has a 50 day moving average price of $4.88 and a 200 day moving average price of $4.58. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.53 and a quick ratio of 1.01.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum raised their price objective on Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th.

Insider Activity at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 5,541 shares of the firm’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $5.39, for a total transaction of $29,865.99. Following the completion of the transaction, the chief financial officer now owns 25,665 shares of the company’s stock, valued at $138,334.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 15,720 shares of company stock valued at $80,435 in the last ninety days. Corporate insiders own 29.10% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.